Gut Microbiota Functional Biomolecules With Immune-Lipid Metabolism for a Prognostic Compound Score in Epstein-Barr Virus-Associated Gastric Adenocarcinoma: A Pilot Study
Open Access
- 17 October 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 10 (10) , e00074
Abstract
OBJECTIVE: Increasing evidence has indicated an association between gut microbiota in gastrointestinal cancer and clinical outcome. Herein, we aim to develop a prognosis-prediction tool based on an immune-lipid metabolism signature, tumor cell-associated immune microenvironment, and lipid metabolism proteins inferred from the function of gut microbiota. METHODS: 16S gene ribosomal RNA sequencing was performed on 10 fecal samples obtained after tumor resection but before chemotherapy (EBVaGC = 4 and EBVnGC = 6). Least absolute shrinkage and selection operator (LASSO) Cox regression was applied to screening for highly accurate marker proteins. A compound score based on the fraction of screened markers was then constructed using a LASSO logistic regression model. RESULTS: The Tax4Fun analysis based on Kyoto Encyclopedia of Genes and Genomes data indicated differentially expressed tumor pathway between EBVnGC and EBVaGC. Using the LASSO logistic model, a compound score was established consisting of 14 types of immune microenvironment and lipid metabolism proteins. In the training set (378 patients), significant differences were found between high- and low-compound score groups in overall survival across and within subpopulations with an identical EBV. Multivariable analysis revealed that the compound score was an independent prognostic factor (hazard ratio, 2.26; 95% confidence interval = 2.28–3.36). The prognostic value ;of the compound score was also confirmed in the validation (162 patients) and entire (540 patients) sets. DISCUSSION: The proposed compound score is a promising signature for estimating overall survival in patients with gastric cancer having EBVaGCs or EBVnGCs.Keywords
This publication has 25 references indexed in Scilit:
- Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectivesEuropean Journal of Cancer, 2016
- Epstein–Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancerGastric Cancer, 2015
- Microbiota-Dependent Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an Immunologically Privileged SiteImmunity, 2015
- Implication of Leptin-Signaling Proteins and Epstein-Barr Virus in Gastric CarcinomasPLOS ONE, 2015
- Deregulation of Immune Response Genes in Patients With Epstein-Barr Virus-Associated Gastric Cancer and OutcomesGastroenterology, 2015
- Fecal microbiota transplantation: effectiveness, complexities, and lingering concernsMucosal Immunology, 2014
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor MicroenvironmentScience, 2013
- Metagenomic biomarker discovery and explanationGenome Biology, 2011
- Host Inflammatory Response Predicts Survival of Patients With Epstein-Barr Virus–Associated Gastric CarcinomaGastroenterology, 2010
- EBV-Positive Gastric Adenocarcinomas: A Distinct Clinicopathologic Entity With a Low Frequency of Lymph Node InvolvementJournal of Clinical Oncology, 2004